Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice.
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Genital warts; Human papillomavirus infections; Penile cancer; Vulvovaginal cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 31 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2010 New trial record